Business context and reporting period
The supplied filing is IKONICS Corporation’s unaudited Form 10-Q for the quarter ended September 30, 2015, filed November 12, 2015. This does not match the request metadata naming TeraWulf Inc.; verify the issuer and filing before relying on this summary. IKONICS reports five segments: Domestic, Export, IKONICS Imaging, Digital Texturing (DTX), and Advanced Material Solutions (AMS).
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Net sales | 2015: $4.543 million; 2014: $4.478 million | 2015: $12.794 million; 2014: $13.867 million |
| Gross profit and margin | 2015: $1.618 million, 35.6%; 2014: $1.628 million, 36.4% | 2015: $4.358 million, 34.1%; 2014: $5.098 million, 36.8% |
| Operating income (loss) | 2015: $189,388; 2014: $176,659 | 2015: $(86,696); 2014: $784,812 |
| Net income (loss) | 2015: $116,756; 2014: $138,971 | 2015: $(84,467); 2014: $542,318 |
| Basic and diluted EPS | 2015: $0.06; 2014: $0.07 | 2015: $(0.04); 2014: $0.27 |
For the first nine months, operating cash flow was $796,792, versus $1.177 million in 2014. Capital spending on property, equipment, and construction in progress was $1.196 million; cash increased $1.100 million to $3.037 million. At September 30, cash and short-term investments totaled $3.262 million; current assets were $8.278 million and current liabilities $1.486 million. Total liabilities were $2.031 million, including $545,000 of deferred income taxes. No debt was outstanding. A secured $2.05 million revolving credit line, priced at 1.8 percentage points above 30-day LIBOR, remained unused and expires May 31, 2017.
Material changes versus the prior comparable period
- Third-quarter sales rose about 1.4%, but nine-month sales fell 7.7%. Nine-month IKONICS Imaging sales declined $829,000, partly reflecting a large 2014 distributor stocking order; Export fell $290,000 and Domestic fell $245,000. AMS sales increased $158,000 and DTX increased $133,000.
- Nine-month gross margin fell 2.7 percentage points, reflecting the absence of the higher-margin 2014 stocking order, weaker higher-margin European sales, and lower Domestic volume. SG&A rose to $3.939 million from $3.823 million, while R&D increased to $506,197 from $489,954.
- Nine-month results included a $45,873 loss from abandoning patent applications. Third-quarter 2014 SG&A benefited from a $46,000 net gain on asset sales, including a $49,000 land-sale gain.
- Cash from operations declined year over year. Inventory reduction provided $352,289 of operating cash in 2015, while higher receivables used $186,283.
Outlook, commitments, and risks
IKONICS expected approximately $150,000 of additional 2015 capital expenditures, excluding its building expansion. The planned 27,300-square-foot expansion, primarily for AMS, was estimated at $3.5 million, with completion expected in the second quarter of 2016; $964,000 had been incurred through September 30. A new ERP system was expected to cost about $400,000 and also be completed by the second quarter of 2016. Management expected to fund spending with cash, operating cash flow, the credit line, and potentially term financing. It anticipated short-term aggregate gross-profit pressure as AMS production costs increase from the second half of 2016.
Management described progress on AMS aerospace feasibility programs and DTX product initiatives, but said prospective programs could lead to ongoing business rather than reporting guaranteed awards. It also cited competitive pressure in Domestic, weaker European conditions, and a strong U.S. dollar. Management believed available resources were sufficient for current and anticipated operations. Forward-looking outcomes remain subject to risks identified in the company’s prior filings. No off-balance-sheet arrangements or legal proceedings were reported; management stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Key facts for investors to verify
- Confirm that IKONICS Corporation, not TeraWulf Inc., is the intended issuer and that the 2015 third-quarter period is correct.
- Review the causes and persistence of the nine-month revenue decline, lower gross margin, and operating loss.
- Check the expansion’s remaining funding needs, final cost, completion timing, and any borrowing or term-financing plans.
- Assess whether AMS and DTX feasibility work converts into recurring commercial sales, and whether expected AMS cost increases affect margins as described.
- Consider timing-related DTX sales and the one-time 2014 distributor stocking order when comparing periods.